Survodutide

Overview

Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).

Mechanism of Action

GLP-1R + GCGR co-agonism (similar to retatrutide's GLP-1/glucagon arms, without GIP). The glucagon arm drives thermogenesis and hepatic fat clearance — the basis for the MASH program — while GLP-1 suppresses appetite and slows gastric emptying.

Research Summary

Phase 2 MASH trial (Sanyal et al., NEJM 2024; 48 weeks, F1–F3 fibrosis): MASH resolution without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) vs 14% placebo. Phase 2 obesity trial reported ~19% weight loss at 46 weeks at the highest dose. Dose-dependent heart-rate elevation has been observed.

Vendors selling Survodutide

Scored vendors carrying Survodutide, ranked by trust grade. Grades are computed from indexed Certificates of Analysis. Full $/mg pricing is on the comparison page.

Reported Side Effects

• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Dose-dependent heart-rate elevation

Compare Survodutide with Others

Research References

• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (Sanyal AJ et al., NEJM) (2024)
• Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two Phase III trials in MASH for survodutide (2024)

Frequently asked questions

Has Survodutide been independently lab-tested?

Disclosed Labs has collected 12 Certificates of Analysis (COA) for Survodutide from 4 independent testing labs. 8 vendors have submitted material for testing. Products average 99.7% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/survodutide/testing.

What is the average purity of Survodutide on the market?

Based on 12 COAs analyzed by Disclosed Labs, Survodutide products average 99.7% (±0.2%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/survodutide/coas.

Where can researchers source Survodutide?

7 vendors with Disclosed Labs trust grades currently list Survodutide, including Peptidology, Skye Peptides, Optima Supply. Compare live prices and lab-verified COAs at https://www.disclosedlabs.com/prices/survodutide.

How does Survodutide work?

GLP-1R + GCGR co-agonism (similar to retatrutide's GLP-1/glucagon arms, without GIP). The glucagon arm drives thermogenesis and hepatic fat clearance — the basis for the MASH program — while GLP-1 suppresses appetite and slows gastric emptying.

What does the research say about Survodutide?

Phase 2 MASH trial (Sanyal et al., NEJM 2024; 48 weeks, F1–F3 fibrosis): MASH resolution without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) vs 14% placebo. Phase 2 obesity trial reported ~19% weight loss at 46 weeks at the highest dose. Dose-dependent heart-rate elevation has been observed.